TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial for the Treatment of Postnatal Depression
Brief Summary: A randomized clinical trial was carried out at primary care level in Santiago, Chile to investigate a combined treatment for women suffering post-natal depression and preventing the adverse consequences of this illness on infant's growth and development.


Options:
A: Arm Label: Enhanced Usual Care (EUC); Type: OTHER; Interventions: Other: EUC | Arm Label: THPP-P; Type: EXPERIMENTAL; Interventions: Behavioral: THPP-P, Other: EUC | Intervention Type: BEHAVIORAL; Name: THPP-P; Assigned to Arm(s): THPP-P | Intervention Type: OTHER; Name: EUC; Assigned to Arm(s): Enhanced Usual Care (EUC), THPP-P
B: Arm Label: PND-MCI; Type: EXPERIMENTAL; Interventions: Other: multi-component intervention | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multi-component intervention; Assigned to Arm(s): PND-MCI | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care
C: Arm Label: Group problem management plus; Type: EXPERIMENTAL; Interventions: Behavioral: Group problem management plus | Arm Label: Enhanced treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Group problem management plus; Assigned to Arm(s): Group problem management plus | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): Enhanced treatment as usual
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PC101+Mental Health | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PC101+Mental Health | Intervention Type: BEHAVIORAL; Name: PC101+Mental Health; Assigned to Arm(s): Control, Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lufwanyama Neonatal Survival Project
Brief Summary: We seek to determine whether we can reduce day 28 mortality in Zambian newborns by training traditional birth attendants a modified version of the neonatal resuscitation protocol (NRP) and by improving their abiltiy to identify sepsis and initiate antibiotics in the field.


Options:
A: Arm Label: EMONC: Community mobilization, HBLSS and Facility Improvement; Type: EXPERIMENTAL; Interventions: Behavioral: Community Mobilization, HBLSS and facility improvement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community Mobilization, HBLSS and facility improvement; Assigned to Arm(s): EMONC: Community mobilization, HBLSS and Facility Improvement
B: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Neonatal resuscitation protocol | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Neonatal resuscitation protocol; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): control
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-support for exclusive breastfeeding | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer-support for exclusive breastfeeding; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lufwanyama Neonatal Survival Project
Brief Summary: We seek to determine whether we can reduce day 28 mortality in Zambian newborns by training traditional birth attendants a modified version of the neonatal resuscitation protocol (NRP) and by improving their abiltiy to identify sepsis and initiate antibiotics in the field.


Options:
A: Arm Label: Facilities; Type: OTHER; Interventions: Other: HBB/ENC supplies | Arm Label: Master Trainers; Type: OTHER; Interventions: Behavioral: HBB/ENC Training and Equipment | Arm Label: Facilitators; Type: OTHER; Interventions: Behavioral: HBB/ENC Training and Equipment | Arm Label: Learners; Type: OTHER; Interventions: Behavioral: HBB/ENC Training and Equipment | Intervention Type: BEHAVIORAL; Name: HBB/ENC Training and Equipment; Assigned to Arm(s): Facilitators, Learners, Master Trainers | Intervention Type: OTHER; Name: HBB/ENC supplies; Assigned to Arm(s): Facilities
B: Arm Label: NRP Training (Intervention); Type: EXPERIMENTAL; Interventions: Procedure: Neonatal Resuscitation | Arm Label: Control; Type: OTHER; Interventions: Procedure: Neonatal Resuscitation | Intervention Type: PROCEDURE; Name: Neonatal Resuscitation; Assigned to Arm(s): Control, NRP Training (Intervention)
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Neonatal resuscitation protocol | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Neonatal resuscitation protocol; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): control
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PRONTO training; Type: EXPERIMENTAL; Interventions: Other: PRONTO training | Intervention Type: OTHER; Name: PRONTO training; Assigned to Arm(s): PRONTO training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lufwanyama Neonatal Survival Project
Brief Summary: We seek to determine whether we can reduce day 28 mortality in Zambian newborns by training traditional birth attendants a modified version of the neonatal resuscitation protocol (NRP) and by improving their abiltiy to identify sepsis and initiate antibiotics in the field.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Neonatal resuscitation protocol | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Neonatal resuscitation protocol; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): control
B: Arm Label: NRP Training (Intervention); Type: EXPERIMENTAL; Interventions: Procedure: Neonatal Resuscitation | Arm Label: Control; Type: OTHER; Interventions: Procedure: Neonatal Resuscitation | Intervention Type: PROCEDURE; Name: Neonatal Resuscitation; Assigned to Arm(s): Control, NRP Training (Intervention)
C: Arm Label: Mentor Mothers Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer support and mentoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer support and mentoring; Assigned to Arm(s): Mentor Mothers Intervention
D: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lufwanyama Neonatal Survival Project
Brief Summary: We seek to determine whether we can reduce day 28 mortality in Zambian newborns by training traditional birth attendants a modified version of the neonatal resuscitation protocol (NRP) and by improving their abiltiy to identify sepsis and initiate antibiotics in the field.


Options:
A: Arm Label: Arm1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Community Based | Intervention Type: OTHER; Name: Community Based; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: IMNCI | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: IMNCI; Assigned to Arm(s): 1
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Neonatal resuscitation protocol | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Neonatal resuscitation protocol; Assigned to Arm(s): intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): control
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin & Amoxicillin x 7days | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard reference therapy | Intervention Type: DRUG; Name: Gentamicin & Amoxicillin x 7days; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Standard reference therapy; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. Two trial periods: A 26 week randomised, followed by a 52 week extension (14 + 38 weeks) where all subjects received liraglutide + OAD after previous randomisation to either liraglutide or exenatide, both combined with OAD treatment.


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide
B: Arm Label: Saxagliptin, 5 mg + insulin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, 5 mg + insulin | Arm Label: Placebo + insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + insulin | Intervention Type: DRUG; Name: Saxagliptin, 5 mg + insulin; Assigned to Arm(s): Saxagliptin, 5 mg + insulin | Intervention Type: DRUG; Name: Placebo + insulin; Assigned to Arm(s): Placebo + insulin
C: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
D: Intervention Type: DRUG; Name: muraglitazar; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. Two trial periods: A 26 week randomised, followed by a 52 week extension (14 + 38 weeks) where all subjects received liraglutide + OAD after previous randomisation to either liraglutide or exenatide, both combined with OAD treatment.


Options:
A: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
B: Arm Label: Lira 1.8; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Lira 1.2; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glimepiride - 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Arm Label: Glimepiride - 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glimepiride - 1, Glimepiride - 2 | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 1.2, Lira 1.8 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 2
C: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide
D: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. Two trial periods: A 26 week randomised, followed by a 52 week extension (14 + 38 weeks) where all subjects received liraglutide + OAD after previous randomisation to either liraglutide or exenatide, both combined with OAD treatment.


Options:
A: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
B: Arm Label: Lira placebo/Lira 2.4 mg/Lira 3.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Lira 1.2 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 1.8 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 2.4 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Orlistat; Type: ACTIVE_COMPARATOR; Interventions: Drug: orlistat | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 mg/Lira 3.0 mg, Lira 1.8 mg/Lira 3.0 mg, Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg | Intervention Type: DRUG; Name: orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira placebo/Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg
C: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: exenatide once weekly, Drug: placebo tablet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sitagliptin, Drug: placebo once weekly | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone, Drug: placebo once weekly | Intervention Type: DRUG; Name: exenatide once weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo tablet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo once weekly; Assigned to Arm(s): 2, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder
Brief Summary: The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) who have comorbid major depressive disorder or dysthymic disorder.


Options:
A: Intervention Type: DRUG; Name: acetazolamide; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Donepezil; Type: EXPERIMENTAL; Interventions: Drug: donepezil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: donepezil; Assigned to Arm(s): Donepezil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DEVICE; Name: CPAP (Continuous Positive Airway Pressure); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Infusion of High Dose Omeprazole Versus Regular Dose Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers
Brief Summary: Bleeding peptic ulcers are one of the major causes of morbidity and mortality for hospital emergency admissions.The initial treatment is endoscopic therapy followed by intravenous omeprazole. However the optimal dosage of omeprazole is not known. We conducted this study to find out the optimal dosage in such clinical scenario.


Options:
A: Arm Label: lansoprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: lansoprazole | Arm Label: esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole | Intervention Type: DRUG; Name: lansoprazole; Assigned to Arm(s): lansoprazole | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): esomeprazole
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Proton pump inhibitor (lansoprazole) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Proton pump inhibitor (lansoprazole) | Intervention Type: DRUG; Name: Proton pump inhibitor (lansoprazole); Assigned to Arm(s): 1, 2
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omeprazole | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FRAGMATIC - A Randomised Phase III Clinical Trial Investigating the Effect of FRAGMin Added to Standard Therapy In Patients With Lung Cancer
Brief Summary: RATIONALE: Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients with lung cancer. It is not yet known whether dalteparin is effective in preventing blood clots in patients with lung cancer.

PURPOSE: This randomized phase III trial is studying how well dalteparin works in preventing blood clots in patients with lung cancer.


Options:
A: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy at the investigator's discretion | Arm Label: dalteparin; Type: EXPERIMENTAL; Interventions: Drug: daltéparine, Drug: Chemotherapy at the investigator's discretion | Intervention Type: DRUG; Name: daltéparine; Assigned to Arm(s): dalteparin | Intervention Type: DRUG; Name: Chemotherapy at the investigator's discretion; Assigned to Arm(s): chemotherapy, dalteparin
B: Arm Label: Group 1: Dalteparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin | Arm Label: Group 2: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Group 1: Dalteparin
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FRAGMATIC - A Randomised Phase III Clinical Trial Investigating the Effect of FRAGMin Added to Standard Therapy In Patients With Lung Cancer
Brief Summary: RATIONALE: Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients with lung cancer. It is not yet known whether dalteparin is effective in preventing blood clots in patients with lung cancer.

PURPOSE: This randomized phase III trial is studying how well dalteparin works in preventing blood clots in patients with lung cancer.


Options:
A: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy at the investigator's discretion | Arm Label: dalteparin; Type: EXPERIMENTAL; Interventions: Drug: daltéparine, Drug: Chemotherapy at the investigator's discretion | Intervention Type: DRUG; Name: daltéparine; Assigned to Arm(s): dalteparin | Intervention Type: DRUG; Name: Chemotherapy at the investigator's discretion; Assigned to Arm(s): chemotherapy, dalteparin
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
C: Arm Label: Group 1: Dalteparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin | Arm Label: Group 2: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Group 1: Dalteparin
D: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: D